Pilot Study Of The Effect Of A CCR5 Coreceptor Antagonist On The Latency And Reservoir Of HIV-1 In Patients Taking Highly Active Antiretroviral Therapy
Phase of Trial: Phase II
Latest Information Update: 25 May 2016
At a glance
- Drugs Maraviroc (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- 25 Jan 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 22 Oct 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Sep 2013 to 1 Dec 2014.
- 31 Jan 2013 Planned end date changed from 1 Dec 2011 to 1 Sep 2013 as reported by ClinicalTrials.gov.